Thesis Progress Report Presentation19 Jun 2019
Sumatriptan is the first clinically available triptan used to treat migraine, a selective agonist of serotonin 5-hydroxytryptamine 1b/1d receptor. To date the mechanism of the neuroprotection offered by sumatriptan in neurodegenerative diseases is unclear. The present study aimed to evaluate the possible involvement of NMDA, NO and ERK signaling in the neuroprotective effect of sumatriptan by in vivo and in vitro study models. The anticonvulsant activity was evaluated by using pentylenetetrazole (PTZ) induced seizure model. For this purpose, various doses of sumatriptan were administered in NMRI mice. The possible role of NMDA/NO pathway in PTZ induced generalized clonic seizures (GCS) was determined by using NMDA, MK-801, L-NAME, 7-NI, L-ARG and MB. The neuroprotection against glutamate induced cerebellar toxicity was evaluated through cerebellar granule neurons (CGNs) culture studies. Neuronal cell viability was checked by neutral red assay and MTT assay respectively. Nitrite assay by griess reaction was performed to measure nitric oxide levels. Results of study showed that sumatriptan attenuated significantly (p˂0.001) PTZ induced clonic seizure and glutamate toxicity. In conclusion, data of this study demonstrated that sumatriptan could be considered as a neuroprotective agent by acting through NMDA/NO pathway.